Study of Safety and of the Mechanism of BLZ945 in ALS Patients
Diseases of the Nervous System
What is the purpose of this trial?
This is an open label study to evaluate safety, tolerability and brain microglia response in participants with ALS following multiple doses of BLZ945.
- Ages18 years - 75 years
- Trial withNovartis Pharmaceuticals
- Start Date02/28/2022
- End Date04/05/2022
- Last Updated03/09/2022
- Study HIC#2000026495